Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Gets Deal With U.S. Government for Covid-19 Neutralizing Antibody

10/28/2020 | 06:15am EST

By Matt Grossman

Eli Lilly & Co. said Wednesday it would supply to the U.S. government 300,000 vials of a neutralizing antibody that could treat Covid-19 in a $375 million deal. The deal is contingent on the antibody's receiving an authorization from the Food and Drug Administration, according to the company.

The arrangement also gives the government the option to buy an additional 650,000 vials of the antibody, called bamlanivimab, through the end of June 2021. Eli Lilly applied in early October for an emergency-use authorization for the antibody's use in high-risk patients with mild to moderate Covid-19.

Under the deal, the U.S. has committed that patients won't be charged for the medication, although health-care facilities could charge a fee to administer it.

Eli Lilly said it is working on distribution plans for the antibody. "The intravenous administration of therapeutics to patients with confirmed mild to moderate Covid-19 presents unique challenges to the healthcare system," the company said.

The company plans to manufacture up to 1 million doses of bamlanivimab by the end of the year and would have 100,000 doses ready to ship within days of authorization, it said.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

10-28-20 0714ET

All news about ELI LILLY AND COMPANY
01:59pELI LILLY AND : Berenberg Adjusts Eli Lilly's Price Target to $190 From $150, Re..
MT
01:20pEli Lilly to Acquire Exclusive Rights for Chronic Pain Drug Candidate From As..
MT
01:01pELI LILLY AND : Lilly, Life for a Child and Beyond Type 1 advance partnership to..
PR
11:36aELI LILLY AND : Lilly and Asahi Kasei Pharma Announce License Agreement for Chro..
PR
09:51aLilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLA..
AQ
01/27ELI LILLY AND : to Provide Covid-19 Drug to U.S. Army
DJ
01/27CLOSE UPDATE : Stocks End Sharply Lower Amid Stimulus Worries, Record Loss at Bo..
MT
01/27COVID SCIENCE-Drugs, vaccines less effective vs new virus variants; antibody ..
RE
01/27AbCellera-Discovered Antibody, Bamlanivimab, to be Developed With Antibody VI..
MT
01/27ELI LILLY AND COMPANY : - New data show treatment with Lilly's neutralizing anti..
AQ
More news
Financials (USD)
Sales 2020 24 394 M - -
Net income 2020 5 805 M - -
Net Debt 2020 11 347 M - -
P/E ratio 2020 32,6x
Yield 2020 1,43%
Capitalization 188 B 188 B -
EV / Sales 2020 8,18x
EV / Sales 2021 7,16x
Nbr of Employees 33 625
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 195,97 $
Last Close Price 207,57 $
Spread / Highest target 13,2%
Spread / Average Target -5,59%
Spread / Lowest Target -42,2%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY22.94%188 179
JOHNSON & JOHNSON6.67%441 951
ROCHE HOLDING AG3.62%309 011
NOVARTIS AG0.20%212 810
PFIZER INC.-1.55%201 436
MERCK & CO., INC.-5.78%194 990